Find A Research Study


Study Title: Treatment of Early Aggressive Rheumatoid Arthritis
Category: Arthritis

Currently accepting participants?
Not at this time.

Principal Investigator: Jeffrey Carlin MD
Study Coordinator: Jill Zeller RN
Phone: 206-223-6835
Email: jill.zeller@vmmc.org

What is the Treatment of Early Aggressive Rheumatoid Arthritis study?

Subjects will be randomized into 2 different comparing arms of drug combinations.

Who can participate?

Subjects must be 18 years old or greater, must have a diagnosis of RA as defined by ACR criteria, and must have active disease at the time of screening.

Study Summary:

The TEAR trial represents the first 2-year trial to analyze the long-term outcomes of treatment of early aggressive rheumatoid arthritis with combinations of FDA-approved drugs.

Detailed Study Description:

(No information)

Study Design: Blinded
Phase of Study: Phase IV
Study Type: Interventional
Condition or Study Focus: Rheumatoid Arthritis
Intervention Type: Drug
Intervention Name: Combinations of FDA-approved: methotrexate, hydroxychoroquine, sulfasalazine and etanercept.
Gender: Male and Female
Age group: Interventional
Sponsor: University of Alabama at Birmingham



Other studies in this category include:

Studies currently accepting study participants:

Studies currently not accepting study participants: